COVID-Focused Biotech Firm Eyeing $675M SPAC Merger
COVID-19 drug developer Direct Biologics LLC and special-purpose acquisition company Good Works II Acquisition Corp. said Tuesday they have conditionally agreed to merge in a deal that would take Direct Biologics...To view the full article, register now.
Already a subscriber? Click here to view full article